Results 121 to 130 of about 38,260 (246)

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy, Andrea Glidden, Tracy Locke, Amy Scales, Elizabeth Gatewood, Jean‐Philippe Blanck, Jessica Castaneda‐Gill, Sharlin Patel, Yolanda D. Mahnke, Xuan Wang, Page Blas   +10 more
wiley   +1 more source

Chemotherapy-Induced Nausea and Vomiting #285 [PDF]

Journal of Palliative Medicine, 2014
Nishant, Tageja, Hunter, Groninger
openaire   +2 more sources

The Impact of the G8 Score on Survival Outcomes in Patients With Head and Neck Cancer Undergoing Concurrent Radiotherapy With Cetuximab due to Contraindications With Cisplatin

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Purpose Patients unable to receive cisplatin due to age, comorbidities, or reduced performance status are commonly treated with concurrent radiotherapy (RT) and cetuximab. This study evaluated the prognostic significance of the Geriatric 8 (G8) score and the Charlson Comorbidity Index (CCI) in predicting survival outcomes in this population ...
Esin Kiraz, Mete Gündoğ, Rıdvan Gönül, İrfan Kara, İmdat Yüce, Sedat Çağlı   +5 more
wiley   +1 more source

Phase II study of pregabalin for the prevention of chemotherapy induced nausea and vomiting

O Mundo da Saúde
To evaluate the role of pregabalin in the protection of chemotherapy-induced nausea and vomiting, we performed a phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin could improve the complete control of nausea ...
Carla Santos Rossi Paniquar, Auro del Giglio, Alayne Magalhães Trindade Domingues Yamada, Felipe José Silva Melo Cruz   +3 more
doaj   +1 more source

Marked Bone Marrow Eosinophilia Post‐Azacitidine + Ivosidenib Treatment for Acute Myeloid Leukemia

International Journal of Laboratory Hematology, EarlyView.
Christopher Liwski, Curtis Marcoux, David M. Conrad   +2 more
wiley   +1 more source

Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi, Stephen Twumasi, Linda K. Olaga, Benedict Sackey, Daniel N. M. Antonio, Richard O. Ansah, Eugene A. Ansah, John A. Sah, Enoch O. Anto, Yvonne Anang‐Quartey, Antoinette Koomson, Angela Opoku, Godfred A. Donkor, Paulina Duah, Ama G. Boadu, Samuel Essien‐Baidoo, Wina I. O. Boadu, Lilian A. Boateng   +17 more
wiley   +1 more source

Multifaceted Roles of Chloroquines in Gastrointestinal Disorders and Beyond

Comprehensive Physiology, Volume 16, Issue 4, August 2026.
Chloroquine (CQ) and hydroxychloroquine (HCQ) modulate lysosomal activity and autophagy, suppressing gastrointestinal inflammation and reshaping pathogenic microbiota. These mechanisms alleviate inflammatory bowel disease, inhibit associated tumor growth, and provide benefits in certain autoimmune and viral conditions.
Sihyun Jeong, Eunsoo Kim, Yong Sung Kim, Eunok Im   +3 more
wiley   +1 more source

Effect of neiguan acupoint pressure on improving chemotherapy⁃induced nausea and vomiting in cancer patients:a Meta analysis

Huli yanjiu, 2020
ObjectiveTo systematically evaluate the clinical effect of neiguan acupoint pressure on improving chemotherapy-induced nausea and vomiting in cancer patients.MethodThe RCTs related to effect of neiguan acupoint pressure on improving chemotherapy-induced ...
CHEN Feng, YANG Xue, LIU Li, LI Le, WANG Yiping   +4 more
doaj  

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 387-393, August 2026.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives [PDF]

, 2016
Nellowe Candelario, Marvin Louis Roy Lu Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA Abstract: Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents.
Candelario N, Lu MLR
core